CFM
CERE

Catalyst Funds Management’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Catalyst Funds Management’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,800
Closed -$114K – 1665
2024
Q2 		$114K Buy
+2,800
New +$117K 0.03% 264

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Catalyst Funds Management's CERE Position: Q3 2024 in Review

Catalyst Funds Management sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 2,800 shares — an estimated $114K sold.

Catalyst Funds Management first reported a position in CERE in Q2 2024 and held it in 1 quarter. The position peaked at $114K in Q2 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Catalyst Funds Management reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Catalyst Funds Management sold 2,800 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $114K.
  • Catalyst Funds Management first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q2 2024 and held it in 1 quarter.
  • Catalyst Funds Management's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $114K in Q2 2024.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Catalyst Funds Management's 13F filing for Q3 2024, filed 14 Nov 2024.